X

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solbinsiran (Primary)
Indications Dyslipidaemias
Focus Therapeutic Use
Acronyms PROLONG-ANG3
Sponsors Eli Lilly and Company

Most Recent Events

25 Jul 2024 Status changed from active, no longer recruiting to completed.
28 Jul 2023 Planned End Date changed from 25 Apr 2024 to 3 Jun 2024.
28 Jul 2023 Planned primary completion date changed from 26 Jan 2024 to 5 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com